The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...

Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Princeton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) ...

Interest in developing nasal dosage forms has increased significantly in the last two years, driven by a number of recent ...

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous ...

Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against ...

FST, fentanyl sublingual tablets; NIm, noninferiority margin; SCM, subcutaneous morphine ... Patient preference was strikingly in favor of the sublingual route (93%). These results support the ...

VK2735 Presses On With Dual Routes Of Administration As I noted above, the company is pressing on with both the oral and subcutaneous versions of VK2735 for the treatment of patients with obesity.

A prespecified interim futility analysis of the subcutaneous data has, however, led Lundbeck to stick with the IV delivery route. Lundbeck, which performed the analysis after enrolling 75% of the ...

The study met its primary endpoints, demonstrating noninferior pharmacokinetics (PK) for subcutaneous pembrolizumab administered ... application to introduce a new pharmaceutical form and new route of ...

In the study, researchers wrote, “Subcutaneous administration has emerged as an alternative route to [intravenous] infusion for the delivery of large therapeutic proteins. Studies show that patients ...